Ubs Group Ag Tricida, Inc. Call Options Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2019

Feb 14, 2020
BUY
$29.6 - $43.71 $150,960 - $222,921
5,100 New
5,100 $192,000

Others Institutions Holding TCDA

# of Institutions
4
Shares Held
30K
Call Options Held
124K
Put Options Held
46.5K
View Full List

About Tricida, Inc.

TCDA Quotes by TradingView
  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email